395 related articles for article (PubMed ID: 33442728)
1. ACE/ACE2 balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases.
Bank S; De SK; Bankura B; Maiti S; Das M; A Khan G
Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33442728
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
3. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection.
Beyerstedt S; Casaro EB; Rangel ÉB
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):905-919. PubMed ID: 33389262
[TBL] [Abstract][Full Text] [Related]
4. Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.
Ferrara F; Vitiello A
Cardiovasc Toxicol; 2021 Jun; 21(6):498-503. PubMed ID: 33835386
[TBL] [Abstract][Full Text] [Related]
5. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
6. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
[TBL] [Abstract][Full Text] [Related]
7. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
8. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
Hu Y; Liu L; Lu X
Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19.
Kutz A; Conen A; Gregoriano C; Haubitz S; Koch D; Domenig O; Bernasconi L; Mueller B; Schuetz P
Eur J Endocrinol; 2021 Apr; 184(4):543-552. PubMed ID: 33539316
[TBL] [Abstract][Full Text] [Related]
11. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
[TBL] [Abstract][Full Text] [Related]
12. Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection.
Sinha A; Vaggu RG; Swain R; Patnaik S
Curr Microbiol; 2023 Apr; 80(6):194. PubMed ID: 37106165
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
Suh SH; Ma SK; Kim SW; Bae EH
Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
[TBL] [Abstract][Full Text] [Related]
14. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.
Matsuzawa Y; Kimura K; Ogawa H; Tamura K
Hypertens Res; 2022 Jul; 45(7):1147-1153. PubMed ID: 35581498
[TBL] [Abstract][Full Text] [Related]
15. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system at the interface of COVID-19 infection.
Gul R; Kim UH; Alfadda AA
Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Rico-Mesa JS; White A; Anderson AS
Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
[TBL] [Abstract][Full Text] [Related]
18. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19).
Albashir AAD
South Med J; 2021 Jan; 114(1):51-56. PubMed ID: 33398362
[TBL] [Abstract][Full Text] [Related]
19. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
20. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
Lores E; Wysocki J; Batlle D
Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
